Publikationer

Pubmed - Eva Tiensuu Janson

Ett urval av våra publikationer

1. Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. Janson ET, Sorbye H, Welin S, Federspiel B, Grønbæk H, Hellman P, Ladekarl M, Langer SW, Mortensen J, Schalin-Jäntti C, Sundin A, Sundlöv A, Thiis-Evensen E, Knigge U. Acta Oncol. 2014 Oct;53(10):1284-97. doi: 10.3109/0284186X.2014.941999.

2. Mosaic loss of chromosome Y in peripheral blood is associated with shorter survival and higher risk of cancer. Forsberg LA, Rasi C, Malmqvist N, Davies H, Pasupulati S, Pakalapati G, Sandgren J, Diaz de Ståhl T, Zaghlool A, Giedraitis V, Lannfelt L, Score J, Cross NC, Absher D, Janson ET, Lindgren CM, Morris AP, Ingelsson E, Lind L, Dumanski JP. Nat Genet. 2014 Jun;46(6):624-8. doi: 10.1038/ng.2966.

3. TCEB3C a putative tumor suppressor gene of small intestinal neuroendocrine tumors. Edfeldt K, Ahmad T, Åkerström G, Janson ET, Hellman P, Stålberg P, Björklund P, Westin G. Endocr Relat Cancer. 2014 Feb 27;21(2):275-84. doi: 10.1530/ERC-13-0419.

4. Elevated plasma chromogranin A is the first indication of recurrence in radically operated midgut carcinoid tumors. Welin S, Stridsberg M, Cunningham J, Granberg D, Skogseid B, Oberg K, Eriksson B, Janson ET. Neuroendocrinology. 2009;89(3):302-7. doi: 10.1159/000179900.

5. Ghrelin and obestatin in human neuroendocrine tumors: expression and effect on obestatin levels after food intake. Grönberg M, Tsolakis AV, Holmbäck U, Stridsberg M, Grimelius L, Janson ET. Neuroendocrinology. 2013;97(4):291-9

6. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Sorbye H, Welin S, Langer SW, Vestermark LW, Holt N, Osterlund P, Dueland S, Hofsli E, Guren MG, Ohrling K, Birkemeyer E, Thiis-Evensen E, Biagini M, Gronbaek H, Soveri LM, Olsen IH, Federspiel B, Assmus J, Janson ET, Knigge U. Ann Oncol. 2013 Jan;24(1):152-60

7. Expression of ghrelin is correlated to a favorable outcome in invasive breast cancer. Grönberg M, Fjällskog ML, Jirström K, Janson ET. Acta Oncol. 2012 Mar;51(3):386-93

8. Common pathogenetic mechanism involving human chromosome 18 in familial and sporadic ileal carcinoid tumors. Cunningham J, Diaz de Ståhl T, Sjöblom T, Westin G, Dumanski J, Janson ET. Genes Chromosomes and Cancer 2011;50:82-9

9. Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. Welin S, Sorbye H, Sebjornsen S, Knappskog S, Busch C, Oberg K. Cancer. 2011 Oct 15;117(20):4617-22

10. Serotonin-producing Carcinoid Tumours: The presence of a solid growth pattern and/or Ki67 index above 1% identifies patients with a poorer prognosis.Cunningham J, Grimelius L. Sundin A, Agarwal S, Janson ET. Acta Oncologica 2007;46:747-756..

11. Malignant gastric ghrelinoma with hyperghrelinemia. Tsolakis AV, Portela Gomes GM, Stridsberg M, Grimelius L, Sundin A, Eriksson B, Öberg K, Janson ET. J Clin Endocrinol Metabol 2004; 89:3739-3744.

12. Carcinoid tumors - analysis of prognostic factors and survival 301 patients from a referral center. Janson ET, Holmberg L, Stridsberg M, Eriksson B, Theodorsson E, Wilander E, Öberg K. Annals of Oncology 1997; 8: 685-690.